UT Health Services

1. Novartis Pharmaceuticals Corporation $151,162 3 payments
2. AstraZeneca Pharmaceuticals LP $49,186 12 payments
3. Retrophin, Inc. $9,076 2 payments
4. AstraZeneca UK Limited $7,735 2 payments

1. A Phase 2, Randomized, Placebo-Controlled, Participant and Investigator Blinded, Multi-Center Study to Assess Efficacy and Safety of Mas825 for the Treatment of Sars-Cov-2 Infected Patients With Covid-19 Pneumonia and Impaired Respiratory Function $137,422 1 payment
2. A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma $26,123 3 payments
3. A Double masked Placebo controlled Study with Open label Period to Evaluate the Efficacy and Safety of MEDI551 in Adult Subjects with Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders $18,558 1 payment
4. A 12-Month, Open-Label, Multicenter, Randomized, Safety, Efficacy, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Two Regimens of Anti-Cd40 Monoclonal Antibody, Cfz533 VS. Standard of Care Control, in Adult de Novo Liver Transplant Recipients With $11,140 1 payment
5. 024Pkan15004 $9,076 2 payments
6. Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene BRCA Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments $7,735 2 payments
7. A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients with Chronic Kidney Disease $3,023 2 payments
8. A Randomized Double Blind Placebo Controlled Parallel Group Study to Evaluate the Efficacy of Two Doses of Cnp520 in Participants at Risk for the Onset of Clinical Symptoms of Ad $2,600 1 payment
9. This is a non randomized open label study to assess olaparib tablets as a treatment for subjects with different homologous recombination deficiency HRD tumor status and with platinum sensitive relapsed high grade ovarian cancer Subjects should have received at least 2 prior lines of platinum based chemotherapy $749 2 payments
10. This is a randomized open label multi center global Phase III study to assess the efficacy and safety of durvalumab plus tremelimumab combination therapy and durvalumab monotherapy versus sorafenib in the treatment of patients with no prior systemic therapy for unresectable HCC $733 4 payments

1. Other $9,076 2 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.